COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #27
Source   PDF   Share   Tweet
See all 155 studies
5/7
Inconc.
Late treatment study
Geleris et al., NEJM, May 7, 2020, doi:10.1056/NEJMoa2012410 (Peer Reviewed)
Observational Study of Hydroxych loroquine in Hospitalized Patients with Covid-19
There appears to be a major error in this paper. Before propensity matching, 38 control patients had hypertension. After propensity matching, 146 patients had hypertension (Table 1). This is not possible. Even if all propensity matched control patients had hypertension, the control prevalence would only be 14% compared to 49% for treatment. Since patients with hypertension are at much greater risk of mortality (HR 2.12, see [1]), this appears to invalidate the results.
Observational study of 1,446 hospitalized patients showing no significant effect on a combined intubation/death outcome for late treatment.
However, secondary analysis shows the success of HC Q was hidden by combining intubation and death - death / (combined death/intubation) for HC Q was 60% vs. control 89%, for details see: [2].
RCT recommended. No AZ or Zinc. HC Q group much sicker - patients already in mild/moderate ARDS, most of the control group not in ARDS. Control cases received other therapeutics.
combined intubation/death, ↑4.0%, p=0.76
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.
Submit